Shandong Xiwang Pharmaceutical Co., Ltd. has been recognized as a High-tech Enterprise for five consecutive terms.

Shandong Xiwang Pharmaceutical Co., Ltd. has been successfully listed in the "Supplementary Filing List of High-tech Enterprises Certified and Registered by Shandong Provincial Certification Agencies." This marks the fifth consecutive time the company has passed the high-tech enterprise certification since its initial recognition in 2011, fully demonstrating its leading position in technological innovation.

As a core enterprise in the pharmaceutical sector of Xiwang Group, Shandong Xiwang Pharmaceutical has always adhered to the development philosophy of "innovation-driven, quality-first," achieving a series of significant breakthroughs in the research and production of active pharmaceutical ingredients (APIs). The company possesses a national-level enterprise technology center and a postdoctoral research station, establishing a comprehensive innovation system, with annual R&D investment exceeding 8% of sales revenue. In recent years, the company has achieved numerous innovative results in glucose derivatives and pharmaceutical excipients, among which the "High-purity Anhydrous Glucose Preparation Technology" won the first prize of Shandong Provincial Science and Technology Progress Award, and the "Pharmaceutical Maltodextrin Industrialization Project" was included in the National Key New Product Plan.

In terms of products, Shandong Xiwang Pharmaceutical Co., Ltd. currently holds five drug production approval numbers. Its pharmaceutical glucose production scale and market share rank first in China, exceeding 85%. The company's pharmaceutical glucose not only dominates the domestic market but is also exported to over 60 countries and regions worldwide, making it a preferred supplier for many internationally renowned pharmaceutical companies. Furthermore, the company is actively expanding its pharmaceutical excipient business; its maltodextrin, corn starch, and other products have been approved by the National Medical Products Administration and are widely used in the production of various dosage forms of pharmaceuticals, including tablets and capsules.

The Chairman of Shandong Xiwang Pharmaceutical Co., Ltd. stated, "Being recognized as a high-tech enterprise for five consecutive terms is a full affirmation of Shandong Xiwang Pharmaceutical Co., Ltd.'s technological strength and R&D level. In the future, the company will continue to increase R&D investment, accelerate the transformation of innovative achievements, and contribute Xiwang's strength to the high-quality development of the pharmaceutical industry."